Corpay stock analysis: 80.5% gross margins and a 7.3% free cash flow yield earn a model Buy, but debt-to-equity of 2.75 and a near-high price are risks.
@2026 – All Right Reserved.
Category:
Companies
-
-
Retail (Discretionary)US Stocks
Amazon Stock Trades Near Two-Year Highs as Earnings Surge but Free Cash Flow Thins Out
Amazon.com stock analysis: shares near two-year highs with 19.6% revenue growth and 30.6% ROE but thin free cash flow. The model rates AMZN a Hold.
-
BiotechnologyUS Stocks
Faeth Therapeutics Trades Near Its Two-Year High While the Fundamentals Stay Pre-Revenue
Faeth Therapeutics stock analysis: a pre-revenue clinical biotech trading near its two-year high, with no debt, steep losses and a model rating of N/A.
-
BiotechnologyUS Stocks
Madrigal’s Revenue Is Up 71% as Rezdiffra Ramps – the Stock Is Already Near Its Highs
Madrigal Pharmaceuticals stock analysis: 71% revenue growth meets a rich 24x price-to-book near two-year highs. Model signal: Hold.
-
SoftwareUS Stocks
CoreWeave Is Burning $9 Billion a Year to Chase AI Demand – Can the Balance Sheet Keep Up?
CoreWeave stock analysis: 112% revenue growth collides with a -$9.1B free cash flow and 10x leverage. Model signal: Sell.
-
MaxLinear stock analysis: revenue is rebounding 55% but margins stay negative and shares trade near two-year highs. Model signal: Hold.
-
BiotechnologyUS Stocks
IDEAYA Biosciences: Trading Near a Two-Year High While the Model Flags a Sell
IDEAYA Biosciences, Inc. stock analysis: shares sit near a two-year high while a -36.4% gross margin and 25/100 quality score drive a Sell signal.
Newer Posts